Doctor-prescribed videogame for ADHD

Pricing and Business Model

• $99 for 30 days is widely viewed as excessive, especially versus full-price AAA games or generic ADHD meds.
• Many see the subscription model as exploiting ADHD-related executive dysfunction (harder to cancel than to sign up).
• Some argue cost reflects medical R&D, FDA process, and “digital therapeutic” positioning; others call it pure rent-seeking enabled by insurance/FSA/HSA rules.

FDA Status and Clinical Evidence

• Product is regulated as a medical device and went through the De Novo pathway; posters debate whether this constitutes “approval” vs “authorization.”
• FDA required safety and efficacy data, but not necessarily at the same standard as drugs.
• Key endpoint: improvements on TOVA (a computerized attention test). Some trials show statistically significant differences vs control; others are non-significant or lack proper sham controls.
• Several commenters criticize TOVA as weak or poorly correlated with real-life ADHD symptoms; improvements may mostly reflect “training the test.”

Game Design, Engagement, and Compliance

• First‑hand reports describe the game as boring, frustrating, and hard to stick with—ironically problematic for people whose core issue is doing boring tasks.
• Mean compliance in trials (~72%) suggests many kids did not complete prescribed play time.
• Some speculate the boredom and mild frustration are intentional “attention training”; others suspect this is just low production quality.

Role in ADHD Treatment

• Widely agreed it should not replace stimulants or core therapies; even marketing materials present it as an adjunct.
• Several ADHD-diagnosed commenters emphasize that meds have large, well‑proven benefits; they worry this exists mainly for medication‑averse parents.
• Others note that structured “attention training” (reading, hard games, meditation, biofeedback) can help as part of a broader coping toolkit.

Data Privacy and Platform Concerns

• App requires phones/app stores and shares some data with third parties, including for advertising; some view this as unacceptable for a medical product.

Broader Skepticism about Digital Therapeutics and Healthcare

• Many see this as an example of systemic healthcare profiteering and “games as treatment” hype.
• Some countries (e.g., Germany) have similar reimbursed “digital health apps,” and commenters suspect many are low-value cash grabs.

Unclear / Open Questions

• How its real‑world effectiveness compares to ordinary commercial games or other low‑cost interventions remains unclear.
• No independent head‑to‑head trials vs meds, other games, or non‑digital therapies are discussed in the thread.